An introduction to the University of Pennsylvania’s 2018 President’s Innovation Prize Winner: Avisi Technologies.
VisiPlate, Avisi Technologies’s nanoscale ocular implant, has the potential to transform the industry paradigm for glaucoma treatment and vision-loss prevention.
Avisi Technologies is developing VisiPlate to treat glaucoma, the world’s leading cause of irreversible blindness. VisiPlate is a nanotechnology-enabled ocular implant for treating glaucoma more safely and effectively.
University of Pennsylvania President Amy Gutmann today announced the recipients of the 2018 President’s Engagement Prizes and President’s Innovation Prize. Awarded annually, the Prizes provide $100,000 in funding for Penn seniors to design and undertake post-graduation projects that make a positive, lasting difference in the world.
After Rui Jing Jiang W18 and her team, Avisi Technologies won the 2017 Y-Prize technology contest with their idea — an ultra-thin drainage implant, called VisiPlate, to treat glaucoma — they moved through two university accelerators and developed their product through a Penn Engineering lab and the Singh Center for Nanotechnology. “We met a ton of entrepreneurs by just being at Penn, and it fostered a sense of community,” says Jiang. “Being able to get to where we are today is testament to the incredible nature of the technology that was spun out of Penn.”
